JP2023528895A - 結節性硬化症の治療の方法 - Google Patents

結節性硬化症の治療の方法 Download PDF

Info

Publication number
JP2023528895A
JP2023528895A JP2022574675A JP2022574675A JP2023528895A JP 2023528895 A JP2023528895 A JP 2023528895A JP 2022574675 A JP2022574675 A JP 2022574675A JP 2022574675 A JP2022574675 A JP 2022574675A JP 2023528895 A JP2023528895 A JP 2023528895A
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
compound
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528895A5 (enExample
Inventor
ゲオルク ガリバルディ
Original Assignee
ノエマ ファーマ アクツィエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノエマ ファーマ アクツィエンゲゼルシャフト filed Critical ノエマ ファーマ アクツィエンゲゼルシャフト
Publication of JP2023528895A publication Critical patent/JP2023528895A/ja
Publication of JP2023528895A5 publication Critical patent/JP2023528895A5/ja
Priority to JP2025082998A priority Critical patent/JP2025122066A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Medicinal Preparation (AREA)
JP2022574675A 2020-06-05 2021-06-04 結節性硬化症の治療の方法 Pending JP2023528895A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025082998A JP2025122066A (ja) 2020-06-05 2025-05-19 結節性硬化症の治療の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
US63/035,313 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025082998A Division JP2025122066A (ja) 2020-06-05 2025-05-19 結節性硬化症の治療の方法

Publications (2)

Publication Number Publication Date
JP2023528895A true JP2023528895A (ja) 2023-07-06
JP2023528895A5 JP2023528895A5 (enExample) 2024-06-13

Family

ID=76325558

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574675A Pending JP2023528895A (ja) 2020-06-05 2021-06-04 結節性硬化症の治療の方法
JP2025082998A Pending JP2025122066A (ja) 2020-06-05 2025-05-19 結節性硬化症の治療の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025082998A Pending JP2025122066A (ja) 2020-06-05 2025-05-19 結節性硬化症の治療の方法

Country Status (13)

Country Link
US (3) US11684613B2 (enExample)
EP (1) EP4161512A1 (enExample)
JP (2) JP2023528895A (enExample)
KR (2) KR20230027145A (enExample)
CN (1) CN116056701A (enExample)
AU (1) AU2021285273A1 (enExample)
BR (1) BR112022024760A2 (enExample)
CA (1) CA3180794A1 (enExample)
CL (1) CL2022003435A1 (enExample)
IL (2) IL322310A (enExample)
MX (1) MX2022015407A (enExample)
PH (1) PH12023550016A1 (enExample)
WO (1) WO2021245281A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
CN120641098A (zh) * 2023-02-02 2025-09-12 诺埃玛制药公司 Dravet综合征的治疗方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526588A (ja) * 2003-06-05 2006-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー グルタミン酸受容体アンタゴニストであるイミダゾール誘導体
JP2010513378A (ja) * 2006-12-21 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ５受容体アンタゴニストの多形

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
CN100548299C (zh) 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
HRP20080363T3 (hr) 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
JP2013505262A (ja) 2009-09-17 2013-02-14 バンダービルト ユニバーシティー ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CA2845578C (en) 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
TWI924682B (zh) 2020-07-30 2026-05-11 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
US20240285637A1 (en) 2021-07-08 2024-08-29 The Royal Institution For The Advancement Of Learning/Mcgill University Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms
CN119677515A (zh) 2022-06-15 2025-03-21 美国政府健康及人类服务部 使用代谢型谷氨酸受体5拮抗剂或/和大麻素受体1拮抗剂治疗纤维化疾病
EP4584250A4 (en) 2022-09-06 2026-02-25 Biohaven Therapeutics Ltd POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS
US20260124188A1 (en) 2022-10-28 2026-05-07 Orphelion Ab mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal
CN120641098A (zh) 2023-02-02 2025-09-12 诺埃玛制药公司 Dravet综合征的治疗方法
EP4680203A1 (en) 2023-03-14 2026-01-21 Prolevi Bio AB Compositions for sustained release of poorly soluble active ingredients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526588A (ja) * 2003-06-05 2006-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー グルタミン酸受容体アンタゴニストであるイミダゾール誘導体
JP2010513378A (ja) * 2006-12-21 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ５受容体アンタゴニストの多形

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROPSYCHOPHARMACOLOGY, vol. 43, no. 6, JPN6024024077, 2017, pages 1457 - 1465, ISSN: 0005505800 *

Also Published As

Publication number Publication date
IL322310A (en) 2025-09-01
CL2022003435A1 (es) 2023-10-20
US12702661B2 (en) 2026-08-11
PH12023550016A1 (en) 2024-03-11
KR20250116184A (ko) 2025-07-31
US20230100520A1 (en) 2023-03-30
US11998535B2 (en) 2024-06-04
IL298709A (en) 2023-02-01
JP2025122066A (ja) 2025-08-20
BR112022024760A2 (pt) 2023-03-07
WO2021245281A1 (en) 2021-12-09
MX2022015407A (es) 2023-05-16
US20230277513A1 (en) 2023-09-07
EP4161512A1 (en) 2023-04-12
CN116056701A (zh) 2023-05-02
CA3180794A1 (en) 2021-12-09
AU2021285273A1 (en) 2023-01-19
KR20230027145A (ko) 2023-02-27
US20250099445A1 (en) 2025-03-27
US11684613B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
JP2025122066A (ja) 結節性硬化症の治療の方法
JP2012229261A (ja) 神経刺激性ステロイドの医薬組成物及びその使用
JP6126040B2 (ja) ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途
US20250345320A1 (en) Methods of treatment of trigeminal neuralgia
CN112745323B (zh) 枸橼酸爱地那非晶型h及其制备方法和用途
CN109988104B (zh) 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途
CN113214209B (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
JP2020528881A (ja) フェノラミンｇ型結晶、その製造方法並びにその組成物及び用途
CN109721557B (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
WO2024118936A1 (en) 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
TWI735652B (zh) 麴酸之共晶和/或共熔結晶、包含其之組合物與用途
JP2004210703A (ja) ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の結晶の製造方法およびその製剤
CN101684083B (zh) 胍基烷酰胺基取代的四环素衍生物
CN114524769B (zh) 塞来昔布-卡马西平共晶、制备方法、药物组合物和应用
CN115120588B (zh) 大黄酸与槐果碱共晶物及制备方法和其组合物与用途
CN109721558B (zh) 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途
OA21124A (en) Methods of treatment of trigeminal neuralgia.

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240604

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250120